PRINCETON, N.J.--(BUSINESS WIRE)--
Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company
focused on advanced wound and burn care, announces it will be webcasting
its Analyst Day event to be held June 17 in New York City. The program's
objective is to provide investors with more in depth information on the
company's products, operations and growth strategy and will consist of
presentations by members of management and panel discussions featuring
Key Opinion Leaders. The webcast will begin at 4:30 p.m. Eastern time
and is scheduled to end at 6:30 p.m. Eastern time.
To listen to the webcast and view presentation slides, please visit the
investor relations section of www.dermasciences.com,
or click http://www.wsw.com/webcast/cc/dsci/.
The event will also be archived on the Company's website.
The following Key Opinion Leaders will be participating in panel
Discussing insights on the growing field of tissue repair within
- Desmond Bell, DPM, CWS, Limb Salvage and Lower Extremity Wound
Care at First Coast Cardio, Co-founder and Executive Director of
the Save A Leg, Save A Life Foundation
Discussing MEDIHONEY® and its impact on patient's lives
- Kevin Foster, MD, MBA, FACS, Maricopa Burn Center, Phoenix
Discussing their thoughts and experience with AMNIOEXCEL® and
- Barry I. Rosenblum, DPM, Assistant Clinical Professor of Surgery
Harvard Medical School, Beth Israel Deaconess Medical Center
- Dimitrios Lintzeris, DO, CWS, Medical Director Wayne Memorial
Wound Care Center
- Kara Couch, NP, Walter Reed National Military Medical Center
Discussing the growing clinical development plan for DSC127 into
diabetic foot ulcers, scar prevention, and radiation dermatitis
Gere diZerega, MD, Professor, Department of Obstetrics and
Gynecology, University of Southern California; co-inventor of
- Kathleen E. Rodgers, PhD, Associate Professor in the Titus Family
Department of Clinical Pharmacy and Pharmaceutical Economics &
Policy in the School of Pharmacy at the University of Southern
California; co-inventor of DSC127
About Derma Sciences, Inc.
Derma Sciences is a tissue regeneration company focused on advanced
wound and burn care. It offers a line of products with patented
technologies to help better manage chronic and hard-to-heal wounds, many
of which result from diabetes and poor vascular functioning. Its
MEDIHONEY® product is the leading brand of honey-based dressings for the
management of wounds and burns. The product has been shown in clinical
studies to be effective in a variety of indications. TCC-EZ® is its
gold-standard total contact casting system for diabetic foot ulcers.
Other novel products introduced into the $14 billion global wound care
market include XTRASORB® for better management of wound exudate, and
BIOGUARD® for barrier protection against microbes and other
contaminants. Derma Sciences entered the $500 million market for skin
substitute products by licensing AMNIOEXCEL® and AMNIOMATRIX® in the
first quarter of 2014. AMNIOEXCEL was introduced to customers in March
2014 and AMNIOMATRIX was launched in the second quarter. Its
pharmaceutical wound care products include DSC127, which is in Phase 3
clinical trials for the healing of diabetic foot ulcers. This drug
candidate is also part of a BARDA grant program for the
healing/prevention of tissue damage due to ionizing radiation exposure.
The patented API peptide used in DSC127 is also in preclinical testing
for scar prevention/reduction. Derma Sciences also offers a full line of
For more information please visit www.dermasciences.com.
Source: Derma Sciences, Inc.